CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Program Title

Late-Life Depression, Comorbidity and the Newer Antidepressants
Release Date: March-15-03
Credit Expiration Date: March-15-04


T. Craig Nelson, MD
Professor of Psychiatry
Leon J. Epstein MD Chair in Geriatric Psychiatry
Director, Geriatric Psychiatry
University of California at San Francisco
San Francisco, California

C. Lindsay DeVane, PharmD
Professor of Psychiatry & Behavioral Sciences
Director, Laboratory of Drug Disposition & Pharmacogenetics
Department of Psychiatry
Medical University of South Carolina
Charleston, South Carolina

Series Coordinator:
Cindy Porter

Nursing Coordinator:
Helen Holman

Credit Hours



Online Presentation

Program Description


Depression in the late-life population may be associated with more challenging diagnosis and treatment than depression in younger individuals. Comorbid disease (with associated polypharmacy) is often present, and may be difficult to distinguish as causative or a consequence of depression. Depression may, of course, also exist as an independent comorbidity. Pharmacotherapy for the late-life individual is also complicated by age-related pharmacokinetic changes in antidepressant medications.

Program Developer/Facilitator


Target Audience

Pharmacists interested in the management of late-life depression.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Identify depression in late-life patients with concomitant medical disease.
  2. Administer antidepressant medication appropriately in older patients.
  3. Describe the physiologic changes in late-life patients that lead to pharmacokinetic changes in antidepressants.
  4. Discuss the impact of pharmacokinetics and drug interactions on the safe administration of antidepressant medications.


Dr. Nelson has received lecture honoraria from Abbott Laboratories, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Janssen Pharmaceutica Inc., Organon Inc., Pfizer Inc, Pharmacia & Upjohn, Inc. and Wyeth Pharmaceuticals. He has served as a consultant to or on the Advisory Boards of Abbott Laboratories, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Organon Inc., Pfizer Inc and Pharmacia & Upjohn, Inc. He has received research support from Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Janssen Pharmaceutica Inc., Organon Inc. and Pfizer Inc.

Dr. DeVane serves on the Advisory Boards of AstraZeneca, Cephalon, Inc., Eli Lilly and Company and GlaxoSmithKline. He is a Speaker for Janssen Pharmaceutica Inc., Forest Laboratories, Inc. and Pharmacia & Upjohn, Inc. He is a recipient of grants from Eli Lilly and Company, the National Institutes of Health and Wyeth Pharmaceuticals.

Credit Statements

This program was developed by the American Society of Consultant Pharmacists (ASCP) and is approved for 1.0 Contact Hours (0.1 CEU). ASCP is approved by the American Council on Pharmaceutical Education (ACPE) as a provider of continuing pharmaceutical education.

Release date: November 6, 2002; ACPE #: 203-000-02-308-H01

A Statement of Credit will be awarded upon satisfactory completion of a post-test with a score of 70% or better.

This program was offered originally as a live audioconference, ACPE # 203-000-02-308-C01. If you participated in the original audioconference you will not be able to receive continuing pharmaceutical education for this program.

Commercial Support Statements

Supported by an unrestricted educational grant from Pfizer Inc.


  1. Click on the "Start program" icon.
  2. The next screen will permit you to start the program presentation, access other program elements, and take the post-test.
  3. Clicking on "start the program" on this screen will begin the program presentation which will take approximately 1 hour to complete.
  4. You must be registered with in order to complete the post-test. When you click on the post-test button you will be brought to a screen which will confirm your registration status and provide an opportunity to register if you haven't done so previously.
  5. Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CE certificate.

Certificate Fee



None of the contents of this program may be reproduced in any form without prior written permission of the publisher. The opinions expressed in this program are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the American Society of Consultant Pharmacists, or Pfizer Inc. Any medications, or other diagnostic or treatment procedures discussed by the program speaker should not be utilized by clinicians without evaluation of their patients’ conditions and of possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu